Motor Neurone Disease Trial, Recruiting NCT03865420 Sponsor: Columbia University Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT03865420
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any race or ethnicity, male or female
  • People who do not currently have any symptoms of ALS or a related condition called fronto-temporal dementia
  • People who have already had genetic testing that found a gene linked to ALS
  • People who have a parent, sibling, or child who is a confirmed carrier of a gene linked to ALS
  • People who have a parent, sibling, or child who has or had ALS with a confirmed related gene mutation, or who come from a family with multiple ALS diagnoses and a known related gene mutation
  • People considered by the study team to be at high risk of carrying an ALS-related gene mutation, based on a review of family history and genetic information
  • People who are willing to have genetic analysis done, with the choice of whether or not to be told the results
  • People who are able to travel to Columbia University Irving Medical Center every 6 to 24 months for study visits
  • People who are able to understand and agree to the study procedures, or who have a legally authorised representative who is able to do this on their behalf

Who may not be able to join:

  • People with a known diagnosis of HIV (this applies to the part of the study involving biological sample collection)
  • People with a known diagnosis of hepatitis B (this applies to the part of the study involving biological sample collection)
  • People with a known diagnosis of hepatitis C (this applies to the part of the study involving biological sample collection)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matthew Harms, MD, Columbia University

Phone: 347-852-5315

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
11 September 2018
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Time to emergence of symptoms attributable to gene mutations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov